Prevail Therapeutics (PRVL) Misses Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Prevail Therapeutics Reports Second Quarter 2020 Financial Results and Business Highlights
August 11, 2020 6:31 AM EDTPreliminary Data Demonstrates Normalization of CSF GBA1 Enzyme Activity in Parkinsons Disease with GBA1 Mutations and Neuronopathic Gaucher Disease Patients
Company Modifies Protocol for PROPEL Trial of PR001 for Parkinsons Disease Patients with GBA1 Mutations; Expects to Continue Enrollment in Second Half of 2020
PROVIDE Trial of PR001 for Type 2 Gaucher Disease and PROCLAIM Trial of PR006 for Frontotemporal Dementia Patients with GRN Mutations Expected to Initiate Enrollment in Second Half of 2020
$75.0 Million At-The-Market Equity Program
... More
